Research
Mild Alzheimer's patients benefit from 40Hz sensory stimulation in national clinical trial
The Brief
- Cognito Therapeutics announced the results of its pivotal clinical trial in mild Alzheimer's patients on November 16 at the Clinical Trials on Alzheimer's Disease conference in Boston.
- The trial tested a noninvasive, device-based approach using 40Hz sensory stimulation, a technique first discovered at the Picower Institute. The provided sources do not give the trial's efficacy figures.
Why it matters
It reports pivotal-trial results for a noninvasive, device-based Alzheimer's treatment, a different category from drug therapies, so its outcomes will matter to researchers evaluating non-drug interventions.
Who’s affected
- people with mild Alzheimer's disease and their caregivers
- clinicians and researchers in neurodegenerative disease
- #alzheimer
- #clinical trial
- #gamma stimulation
- #neuroscience
- #medical device
At the Clinical Trials on Alzheimer's Disease conference in Boston Nov. 16, MIT spinoff company Cognito Therapeutics announced the results of its pivotal clinical trial of a noninvasive, device-based approach to Alzheimer's disease (AD) treatment first discovered in The Picower…